Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT03352206
• Date of registration: 20/11/2017
• Prospective Registration: No
• Primary sponsor: Washington University School of Medicine
• Public title: Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis
• Scientific title: Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators
• Date of first enrolment: October 18, 2017
• Target sample size: 20092
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT03352206
• Study type: Observational

Countries of recruitment

Fiji, Haiti, India, Indonesia, Papua New Guinea

Contacts

• Name: Gary Weil, MD
• Affiliation: Washington University School of Medicine

Key inclusion & exclusion criteria

Inclusion Criteria:

- Age = 5 years (males and females)

- Able to provide informed consent, or parental/guardian consent for young children, and
assent for older children

Exclusion Criteria:

- Unable or unwilling to provide informed consent or (for minors) lacking
parental/guardian consent to participate in the study



Age minimum: 5 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Lymphatic Filariases

Intervention(s)

Drug: 2 drug dose - DA

Drug: 3 drug dose - IDA

Primary Outcome(s)

Number of participants with IgG4 antifilarial antibodies in plasma [Time Frame: One sample collected about 12 months after exposure to treatment]

Number of participants with microfilaremia as measured with night blood smear testing [Time Frame: One sample collected about 12 months after exposure to treatment]

Number of participants with circulating filarial antigenemia (CFA) as measured by the Filaria Test Strip [Time Frame: One sample collected about 12 months after exposure to treatment]

Secondary Outcome(s)

Prevalence of STH (hookworm, ascaris, trichuris and strongyloides) as measured by Kato-katz or PCR [Time Frame: One comparison about 12 months after exposure to treatment]

Community prevalence of circulating filarial antigen as measured with filarial test strip [Time Frame: One comparison about 12 months after exposure to treatment]

Community prevalence of microfilaremia as measured with night blood smear [Time Frame: One comparison about 12 months after exposure to treatment]

Secondary ID(s)

201710040

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

Indonesia University

Papua New Guinea Institute for Medical Research

Case Western Reserve University

Ministere de la Sante Publique et de la Population, Haiti